Clinical Trial Update: Immunotherapy Study in Progressive or Relapsed Non-Small Cell Lung Cancer [Phase 2, Phase 3]

View source ↗

Summary

Phase 2/3 immunotherapy trial in progressive or relapsed non-small cell lung cancer was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Snippet

Sponsor: NewLink Genetics Corporation | Conditions: Non-small Cell Lung Cancer, Progression of Non-small Cell Lung Cancer | Phase 2, Phase 3 | Status: TERMINATED